Core Viewpoint - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy, emphasizing "innovation-driven, digital empowerment, green transformation, and open cooperation" to enhance its competitiveness across the entire industry chain [1] Group 1 - The company plans to transition from a traditional chemical pharmaceutical enterprise to an innovative, international, diversified, and high-quality pharmaceutical health industry group [1] - The strategic focus includes two dimensions: targeting industry high points and horizontal development in the health sector [1]

Group 1: Strategic Planning and Business Model - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy to enhance profitability and establish a sustainable profit model, maintaining stable growth in line with industry standards [2][3] - The company emphasizes "innovation-driven, digital empowerment, green transformation, and open cooperation" as core strategic directions to build competitive advantages across the entire industry chain [2] Group 2: Impact of Shareholder Changes - After becoming a controlling shareholder in 2018, Fangda Group introduced advanced market-oriented management models, significantly improving Northeast Pharmaceutical's operational efficiency and profitability [4] - The company has shown continuous profit growth over the past five years, indicating resilience and sustainable development capabilities [4] Group 3: Revenue Structure and Future Trends - As of the first three quarters of 2023, the company's revenue structure is stable, with approximately 60% from pharmaceutical manufacturing and 40% from pharmaceutical commerce [6] - Traditional businesses face challenges from industry policies and market competition, while innovative drug segments are expected to drive future growth [6][7] Group 4: Innovation and R&D Developments - The acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotech Co., Ltd. in 2024 allows Northeast Pharmaceutical to enter the TCR-T and CAR-T cell therapy fields, with promising products already in clinical trials [4][6] - Dingcheng Peptide has established a comprehensive R&D system, focusing on cell and gene therapy, and has received multiple recognitions as a high-tech enterprise [9][10] Group 5: Challenges and Market Dynamics - The company faces challenges in balancing high R&D costs with short-term cash flow pressures, particularly in the competitive cell therapy market [7] - The transition from traditional chemical pharmaceuticals to a dual-driven model of traditional and innovative biopharmaceuticals is critical for future growth [7] Group 6: Talent Acquisition and Team Structure - Dingcheng Peptide's R&D team includes 18 PhDs and 59 master's degree holders, ensuring expertise across key areas of drug development [10] - A recruitment plan aims to onboard 300 master's and doctoral graduates by 2025 to strengthen the R&D capabilities in cell therapy [10]

（2） 预计2025年年度实现归属于母公司所有者的净利润约为-26,500.00万元到-22,500.00万元，比上年 同期亏损减少17,572.12万元到21,572.12万元，同比亏损减少39.87%到48.95%。 证券代码：688373 证券简称：盟科药业 公告编号：2026-014 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、 本期业绩预告情况 （一） 业绩预告期间 2025年1月1日至2025年12月31日 （二） 业绩预告情况 （1） 经上海盟科药业股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现营业 收入约为13,500.00万元到15,500.00万元，与上年同期相比，预计增加472.72万元到2,472.72万元，同比 增长3.63%至18.98%。 报告期内，公司营业收入同比实现小幅增长。与此同时，公司通过加强对销售、研发及管理费用的精细 化管控，优化组织架构，提升资源利用效率等措施，使得公司总体成本及费用较上年同期有所下降。综 合以上因素，公司2025年度虽仍处于亏损 ...

江苏联环药业股份有限公司 证券代码：600513 证券简称：联环药业 公告编号：2026-005 第九届董事会第二十一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、会议召集与召开情况 江苏联环药业股份有限公司（以下简称"公司"）第九届董事会第二十一次临时会议于2026年1月23日以 通讯方式召开，本次会议通知于2026年1月19日以电子邮件形式发出。会议应出席董事9名，实际出席董 事9名，出席会议人数符合《公司章程》的规定。本次董事会由公司董事长钱振华先生主持，会议经过 了适当的召集和通知程序，符合《中华人民共和国公司法》等相关法律、法规及《公司章程》的规定， 会议合法有效。 二、董事会会议审议情况 会议就下列议案进行了认真审议，经与会董事投票表决，通过如下决议： （一）审议通过《关于制定〈业务隔离制度〉的议案》 董事会同意公司根据《上市公司治理准则》等法律法规要求以及中国证券投资基金业协会的相关规定， 制定《业务隔离制度》以加强公司风险管理，实现公司与从事基金管理业务的关联公司之间的业务隔 离，从而 ...

Group 1 - The company expects a loss of 54 million to 73 million yuan in 2025, with a non-recurring loss of 62 million to 84 million yuan [1] - The market environment has negatively impacted the company's sales revenue and gross margin due to fluctuations in terminal demand and declining market prices for certain raw material products [1] - The company's operational development is affected by high fixed costs during the gradual release of new production capacity from completed fundraising projects, as well as high unit costs from small-scale production of new health products set to launch in 2025 [1]

Core Viewpoint - Jinkai Biotechnology (301509.SZ) expects a significant increase in net profit for 2025, driven by improved terminal demand and order delivery pace [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 72 million and 91 million yuan, indicating a year-on-year increase of 314.69% to 424.12% [1] Operational Factors - The increase in delivered orders during the reporting period is attributed to the recovery in terminal demand and the rhythm of customer order deliveries [1] - The overall gross profit margin has improved due to the impact of the product structure of delivered orders [1]

（文章来源：证券日报） 证券日报网讯 1月23日，富祥药业发布公告称，公司董事会于近日收到公司副总经理陈应惠先生提交的 书面辞职报告，陈应惠先生因个人原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。 ...

Core Viewpoint - The company, Tuoxin Pharmaceutical, anticipates a significant increase in net profit loss for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, compared to a loss of approximately 19.88 million yuan in the previous year, indicating a decline of 171.56% to 267.11% year-over-year [1] Financial Performance - The projected net profit loss for 2025 is estimated to be between 54 million to 73 million yuan [1] - The previous year's loss was reported at 19.88 million yuan [1] - The anticipated decline in net profit loss represents an increase in losses by 171.56% to 267.11% compared to the previous year [1]

Core Viewpoint - The company, LuKang Pharmaceutical, has announced a plan to utilize part of its idle raised funds for cash management, ensuring that it does not affect the normal operation of investment projects [2] Group 1: Company Announcement - On January 23, 2026, LuKang Pharmaceutical held the twelfth (temporary) meeting of the eleventh board of directors to approve the proposal for cash management using idle raised funds [2] - The company will use an amount not exceeding RMB 31 million for cash management, with a validity period of 12 months from the date of board approval [2] - A dedicated settlement account for cash management products has been opened at the Jining Jin Yu Road Branch of China Postal Savings Bank [2]

人民财讯1月23日电，*ST长药（300391）1月23日公告，公司于2026年1月23日收到深圳证券交易所下 发的《事先告知书》,拟决定终止公司股票上市交易。公司股票自2026年1月26日开市起停牌。 ...